Literature DB >> 9040840

Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Oregon.

L L Blythe1, D E Granstrom, D E Hansen, L L Walker, J Bartlett, S Stamper.   

Abstract

OBJECTIVE: To determine seroprevalence of antibodies to Sarcocystis neurona in neurologically normal horses residing in 4 regions of Oregon and to describe the effects of age, gender, breed, and housing on seroprevalence within each region.
DESIGN: Prevalence survey. SAMPLE POPULATION: Serum samples from 334 horses systematically selected by practicing veterinarians. PROCEDURE: Antibodies to S neurona were measured in sera, using a western blot. Information including age, gender, breed, housing, geographic location, and duration of residence was obtained for each horse. Data were analyzed, using descriptive statistics.
RESULTS: 45% (149/334) of horses evaluated were seropositive for antibodies to S neurona with significant differences in the percentage of seropositive horses from different regions of the state. Seroprevalances of antibodies to S neurona in horses in regions I and II, west of the Cascade Range, were 65 and 60%, respectively; whereas seroprevalances in central and eastern Oregon, regions III and IV, were 43 and 22%, respectively. Seroprevalence consistently increased with age of horse for each region. Gender, breed, and housing were not associated with significant differences in seroprevalence of antibodies to S neurona in the overall sample population, or in comparisons of samples obtained from horses within a particular region, or among samples obtained from horses residing in different regions. CLINICAL IMPLICATIONS: The high seroprevalence of antibodies to S neurona in neurologically normal horses indicates that analysis of serum alone would not be useful for definitive diagnosis of equine protozoal myeloencephalitis in horses in Oregon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040840

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Evidence that surface proteins Sn14 and Sn16 of Sarcocystis neurona merozoites are involved in infection and immunity.

Authors:  F T Liang; D E Granstrom; X M Zhao; J F Timoney
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Enzyme-linked immunosorbent assays for detection of equine antibodies specific to Sarcocystis neurona surface antigens.

Authors:  Jessica S Hoane; Jennifer K Morrow; William J Saville; J P Dubey; David E Granstrom; Daniel K Howe
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

3.  Reduced levels of nitric oxide metabolites in cerebrospinal fluid are associated with equine protozoal myeloencephalitis.

Authors:  Chinedu J Njoku; William J A Saville; Stephen M Reed; Michael J Oglesbee; Päivi J Rajala-Schultz; Roger W Stich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 4.  An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM).

Authors:  J P Dubey; D K Howe; M Furr; W J Saville; A E Marsh; S M Reed; M E Grigg
Journal:  Vet Parasitol       Date:  2015-02-07       Impact factor: 2.738

5.  Cytokine gene expression in response to SnSAG1 in horses with equine protozoal myeloencephalitis.

Authors:  Jennifer A Spencer; Patricia Deinnocentes; Edith M Moyana; Anthony J Guarino; Siobhan E Ellison; R Curtis Bird; Byron L Blagburn
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Prevalence of antibodies to Sarcocystis neurona and Neospora hughesi in horses from Mexico.

Authors:  Michelle R Yeargan; Cosme Alvarado-Esquivel; Jitender P Dubey; Daniel K Howe
Journal:  Parasite       Date:  2013-09-10       Impact factor: 3.000

Review 7.  Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention.

Authors:  S M Reed; M Furr; D K Howe; A L Johnson; R J MacKay; J K Morrow; N Pusterla; S Witonsky
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.